CareGuidePro, a New Mobile App and Online Platform for Patients to Navigate Their Spinal Cord Stimulation Journey

CareGuidePro, is a mobile application and web portal that serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy journey.

The patient’s care team, including physicians and Medtronic, may also use the CareGuidePro platform to help manage and support the patient’s experience with spinal cord stimulation. Patients also have the ability to record their pain relief and other feedback directly into the app, providing detailed Patient Reported Outcomes (PROs) to ensure timely, essential information is recorded and accessible even outside of in-person office visits.

“Pain management is a complex and intensely personal experience for individual patients. Every patient is a singular case. The ability to monitor patients more closely, to receive data and feedback more quickly, means we can adjust and adapt therapies more efficiently and effectively when needed,” said Krishnan Chakravarthy, M.D., Ph.D., a San Diego-based interventional pain management physician and first physician to use the technology with patients. “This is an important step forward for the field of neuromodulation and patient care.”

“Knowledge is power, and digital health solutions like CareGuidePro give patients the tools they need to ask the right questions and make informed care decisions, which we know can lead to better long-term outcomes,” said Nandan Lad, M.D., Ph.D., professor of neurosurgery at Duke University and co-founder of Higgs Boson Health. “By providing patients with the right information at the right time, we also aim to reduce inefficiencies and free up care teams to focus on providing outstanding care.”

“CareGuidePro is Medtronic’s first patient-centric digital health platform created for spinal cord stimulation patients, intended as a seamless solution that will naturally integrate into the care provider’s workflow,” said Dave Anderson, president of the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. “We believe this digital health platform will facilitate a more informative and engaging patient experience that will translate into better physician-patient dialogue, potentially contributing to better therapy management.”

CareGuidePro features include:

  • Caregiver access for patients less familiar or able to manage the app, enabling easy access to essential information
  • Procedure-specific FAQs and task lists/reminders
  • Standardized and Custom Patient Reported Outcomes (PRO) surveys
  • Secure sharing of PROs to keep entire care team informed
  • Secure, encrypted two-way communication and file-sharing

Medtronic is currently enrolling patients for the app’s limited commercial release, with a full United States release expected in late summer. CareGuidePro is available on iOS® and Android™ devices.

SourceMedtronic

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”